Side-by-side · Research reference
BPC-157vsProstamax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED9/53 cited
BAnimal-MechanisticHUMAN-REVIEWED11/38 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
01Mechanism of Action
Parameter
BPC-157
Prostamax
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011Sikiric 2018
Chromatin in prostatic cells — pericentromeric heterochromatin regions
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Feedback intact?
No known endogenous receptor; mechanism still under investigation
—
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
Prostamax
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
—
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
—
Lower / starter dose
200 mcg / day
Conservative starter for new users.
—
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
Reconstitution
Bacteriostatic water, 1–2 mL
—
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
—
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
—
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
Human clinical dose
—
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
Age groups studied
—
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
04Side Effects & Safety
Parameter
BPC-157
Prostamax
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
—
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Published adverse events
—
None reported in available literature
Genotoxicity signals
—
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
Metal ion interactions
—
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
Human safety data
—
Absent — no published Phase 1/2/3 trials
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
05Administration Protocol
Parameter
BPC-157
Prostamax
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
Prostamax
— no documented stacks